{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:55:28Z","timestamp":1793346928210,"version":"4.5.0"},"reference-count":61,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Limited information exists regarding treatment of patients with psoriasis\/psoriatic arthritis in primary care. The aim of this study is to assess treatment patterns, adherence, persistence, and compliance in newly diagnosed patients with psoriasis\/psoriatic arthritis from 2012 to 2018 in Stockholm, Sweden. In addition, laboratory monitoring before initiation of treatment and at recommended intervals was quantified for patients prescribed methotrexate or biologics. A total of 51,639 individuals were included, with 39% initiating treatment with topical corticosteroids and &lt;\u20095% receiving systemic treatment within 6 months post-diagnosis. During a median (interquartile range) follow-up of 7 (4\u20138) years, 18% of patients received systemic treatments at some point. Overall, 5-year persistence rates were 32%, 45% and 19% for methotrexate, biologics, and other systemic treatments, respectively. Pre-initiation laboratory tests, as recommended by guidelines, were performed in approximately 70% and 62% of methotrexate and biologics users, respectively. Follow-up monitoring at recommended time intervals occurred in 14\u201320% and 31\u201333% of patients prescribed methotrexate and biologics, respectively. These findings highlight gaps in the pharmacological care of patients with psoriasis\/psoriatic arthritis, including suboptimal adherence\/persistence and inadequate laboratory monitoring.<\/jats:p>","DOI":"10.2340\/actadv.v103.6505","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:10:07Z","timestamp":1686820207000},"page":"adv6505","source":"Crossref","is-referenced-by-count":14,"title":["Psoriasis\/Psoriatic Arthritis Patients\u2019 Long-term Treatment Patterns and Adherence to Systemic Treatments Monitoring Recommendations"],"prefix":"10.2340","volume":"103","author":[{"given":"\u00c5sa","family":"Krantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovisa","family":"Schalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Lysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"33254","unstructured":"Svensson \u00c5 SO, Thalme T, Schmitt-Egenholf M, Alenius G-M. L\u00e4kemedelsbehandling av psoriasis och psoriasisartrit-bakgrundsdokument. L\u00e4kemedelsverket, 2019: p. 34-35."},{"key":"33255","doi-asserted-by":"crossref","unstructured":"Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet 2018; 391: 2285-2294.","DOI":"10.1016\/S0140-6736(18)30949-8"},{"key":"33256","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(18)30949-8","DOI":"10.1016\/S0140-6736(18)30949-8"},{"key":"33257","unstructured":"World Health Organisation (2014) Resolution on psoriasis (WHA 67.9) by the Sixty-Seventh World Assembly of the World Health Organization, Available from https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R9-en.pdf"},{"key":"33258","doi-asserted-by":"crossref","unstructured":"Ingrasciotta Y, Isgr\u00f2 V, Ientile V, Tari M, Trifir\u00f2 G, Guarneri C. Are patients with psoriasis and psoriatic arthritis undertreated? A population-based study from southern Italy. J Clin Med 2021; 10: 3431.","DOI":"10.3390\/jcm10153431"},{"key":"33259","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm10153431","DOI":"10.3390\/jcm10153431"},{"key":"33260","doi-asserted-by":"crossref","unstructured":"Perrone V, Losi S, Filippi E, Mezzetti M, Dovizio M, Sangiorgi D, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther 2022; 9: 875-890.","DOI":"10.1007\/s40744-022-00440-1"},{"key":"33261","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40744-022-00440-1","DOI":"10.1007\/s40744-022-00440-1"},{"key":"33262","doi-asserted-by":"crossref","unstructured":"Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632-2640.","DOI":"10.1038\/jid.2015.208"},{"key":"33263","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2015.208","DOI":"10.1038\/jid.2015.208"},{"key":"33264","doi-asserted-by":"crossref","unstructured":"Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, Apol E, Hansen JB, Levin L. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther (Heidelb) 2021; 11: 2107-2121.","DOI":"10.1007\/s13555-021-00616-7"},{"key":"33265","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-021-00616-7","DOI":"10.1007\/s13555-021-00616-7"},{"key":"33266","doi-asserted-by":"crossref","unstructured":"Calara PS, Althin R, Carlsson KS, Schmitt-Egenolf M. Regional differences in the prescription of biologics for psoriasis in Sweden: a register-based study of 4168 patients. BioDrugs 2017; 31: 75-82.","DOI":"10.1007\/s40259-016-0209-y"},{"key":"33267","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40259-016-0209-y","DOI":"10.1007\/s40259-016-0209-y"},{"key":"33268","doi-asserted-by":"crossref","unstructured":"Svedbom A, Dal\u00e9n J, Mamolo C, Cappelleri JC, Petersson IF, St\u00e5hle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis. J Eur Acad Dermatol Venereol 2015; 29: 215-223.","DOI":"10.1111\/jdv.12494"},{"key":"33269","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12494","DOI":"10.1111\/jdv.12494"},{"key":"33270","doi-asserted-by":"crossref","unstructured":"Tveit KS, Duvetorp A, \u00d8stergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol 2019; 33: 340-354.","DOI":"10.1111\/jdv.15252"},{"key":"33271","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15252","DOI":"10.1111\/jdv.15252"},{"key":"33272","doi-asserted-by":"crossref","unstructured":"Calara PS, Norlin JM, Althin R, Carlsson KS, Schmitt-Egenolf M. Healthcare provider type and switch to biologics in psoriasis: evidence from real-world practice. BioDrugs 2016; 30: 145-151.","DOI":"10.1007\/s40259-016-0163-8"},{"key":"33273","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40259-016-0163-8","DOI":"10.1007\/s40259-016-0163-8"},{"key":"33274","doi-asserted-by":"crossref","unstructured":"Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Resource use in patients with psoriasis after the introduction of biologics in Sweden. Acta Derm Venereol 2015; 95: 156-161.","DOI":"10.2340\/00015555-1895"},{"key":"33275","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1895","DOI":"10.2340\/00015555-1895"},{"key":"33276","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461-2498.","DOI":"10.1111\/jdv.16915"},{"key":"33277","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16915","DOI":"10.1111\/jdv.16915"},{"key":"33278","doi-asserted-by":"crossref","unstructured":"Carrero JJ, Elinder CG. The Stockholm CREAtinine Measurements (SCREAM) project: Fostering improvements in chronic kidney disease care. J Intern Med 2022; 291: 254-268.","DOI":"10.1111\/joim.13418"},{"key":"33279","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/joim.13418","DOI":"10.1111\/joim.13418"},{"key":"33280","unstructured":"The National Board of Health and Welfare. National guidelines for psoriasis care: Support for governance and management. 2019 [accessed Jan 31, 2022]. Available from: https:\/\/www.socialstyrelsen.se\/regler-och-riktlinjer\/nationella-riktlinjer\/riktlinjer-och-utvarderingar\/psoriasis\/"},{"key":"33281","unstructured":"National Board of Health and Welfare, L\u00e4kemedelsregistret. 2021. [accessed 2022 Jan 31]. Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/lakemedelsregistret\/"},{"key":"33282","unstructured":"Stockholm County County Council. VAL-databaserna. 2022. [accessed 2022 Jan 31]. Available from: https:\/\/www.folkhalsokollen.se\/datakallor\/val-databaserna\/"},{"key":"33283","doi-asserted-by":"crossref","unstructured":"Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-2310.","DOI":"10.1185\/03007990903126833"},{"key":"33284","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1185\/03007990903126833","DOI":"10.1185\/03007990903126833"},{"key":"33285","unstructured":"The Swedish Society for Dermatology and Venereology (SSDV). [SSDV:s behandlingsrekommendationer f\u00f6r systemisk behandling av psoriasis]. 2022. [accessed Jan 31, 2022] Available from: https:\/\/www.ssdv.se\/images\/SSDVs_behandlingsrekommendationer_for_systemisk_behandli_ng_av_psoriasis_2022-05-25.pdf."},{"key":"33286","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol 2013; 149: 1180-1185.","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"33287","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2013.5264","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"33288","doi-asserted-by":"crossref","unstructured":"Lambert J, Ghislain P-D, Lambert J, Cauwe B, Van den Enden M. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). J Dermatolog Treat 2017; 28: 394-400.","DOI":"10.1080\/09546634.2016.1255304"},{"key":"33289","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2016.1255304","DOI":"10.1080\/09546634.2016.1255304"},{"key":"33290","doi-asserted-by":"crossref","unstructured":"Muddasani S, Fleischer AB, Jr., Feldman SR. Treatment practices for psoriasis and how they are changing. J Am Acad Dermatol 2021; 84: 579-581.","DOI":"10.1016\/j.jaad.2020.09.064"},{"key":"33291","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.064","DOI":"10.1016\/j.jaad.2020.09.064"},{"key":"33292","doi-asserted-by":"crossref","unstructured":"Do MH, Schwartz Z, Abedian S, Lipner SR. Trends in psoriasis treatment 2005 to 2018: Declining phototherapy utilization and concomitant increased use of biologics. Dermatol Ther 2020; 33: e14276.","DOI":"10.1111\/dth.14276"},{"key":"33293","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14276","DOI":"10.1111\/dth.14276"},{"key":"33294","unstructured":"Shaw MK, Davis SA, Feldman SR, Fleischer AB, Jr. Trends in systemic psoriasis treatment therapies from 1993 through 2010. J Drugs Dermatol 2014; 13: 917-920."},{"key":"33295","doi-asserted-by":"crossref","unstructured":"Singh P, Silverberg JI. Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol 2020; 83: 256-257.","DOI":"10.1016\/j.jaad.2020.01.045"},{"key":"33296","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.01.045","DOI":"10.1016\/j.jaad.2020.01.045"},{"key":"33297","doi-asserted-by":"crossref","unstructured":"Hiremath AC, Bhandari R, Wali S, Ganachari MS, Doshi B. Impact of clinical pharmacist on medication adherence among psoriasis patients: a randomized controlled study. Clin Epidemiol Glob Health 2021; 10: 100687.","DOI":"10.1016\/j.cegh.2020.100687"},{"key":"33298","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cegh.2020.100687","DOI":"10.1016\/j.cegh.2020.100687"},{"key":"33299","doi-asserted-by":"crossref","unstructured":"Cline A, Unrue EL, Cardwell LA, Alinia H, Tull R, Feldman SR, et al. Internet-based survey intervention improves adherence to methotrexate among psoriasis patients. J Dermatolog Treat 2022; 33: 2784-2789.","DOI":"10.1080\/09546634.2022.2071821"},{"key":"33300","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2022.2071821","DOI":"10.1080\/09546634.2022.2071821"},{"key":"33301","doi-asserted-by":"crossref","unstructured":"Svendsen MT, Andersen F, Andersen KH, Potteg\u00e5rd A, Johannessen H, M\u00f6ller S, et al. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol 2018; 179: 1062-1071.","DOI":"10.1111\/bjd.16667"},{"key":"33302","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16667","DOI":"10.1111\/bjd.16667"},{"key":"33303","doi-asserted-by":"crossref","unstructured":"Piragine E, Petri D, Martelli A, Janowska A, Dini V, Romanelli M, et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med 2022; 11: 1506.","DOI":"10.3390\/jcm11061506"},{"key":"33304","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm11061506","DOI":"10.3390\/jcm11061506"},{"key":"33305","doi-asserted-by":"crossref","unstructured":"Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med 2021; 7: 625755.","DOI":"10.3389\/fmed.2020.625755"},{"key":"33306","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2020.625755","DOI":"10.3389\/fmed.2020.625755"},{"key":"33307","doi-asserted-by":"crossref","unstructured":"Raaby L, Zachariae C, \u00d8stensen M, Heickendorff L, Thielsen P, Gr\u00f8nb\u00e6k H, et al. Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting. Acta Derm Venereol 2017; 97: 426-432.","DOI":"10.2340\/00015555-2599"},{"key":"33308","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2599","DOI":"10.2340\/00015555-2599"},{"key":"33309","doi-asserted-by":"crossref","unstructured":"Sierocinski E, Angelow A, Mainz A, Walker J, Chenot J-F. Patientensicherheit in der Rheumatherapie. Z fur Rheumatol 2021; 80: 418-424.","DOI":"10.1007\/s00393-021-00976-7"},{"key":"33310","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00393-021-00976-7","DOI":"10.1007\/s00393-021-00976-7"},{"key":"33311","doi-asserted-by":"crossref","unstructured":"Fraser SD, Lin SX, Stammers M, Culliford D, Ibrahim K, Barrett R, et al. Persistently normal blood tests in patients taking methotrexate for RA or azathioprine for IBD: a retrospective cohort study. Br J Gen Pract 2022; 72: e528-e537.","DOI":"10.3399\/BJGP.2021.0595"},{"key":"33312","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3399\/BJGP.2021.0595","DOI":"10.3399\/BJGP.2021.0595"},{"key":"33313","doi-asserted-by":"crossref","unstructured":"Mazaud C, Fardet L. Daily practices regarding safety monitoring of low-dose methotrexate and comparison to guidelines: a population-based cohort study. Therapie 2021; 76: 425-433.","DOI":"10.1016\/j.therap.2019.05.004"},{"key":"33314","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.therap.2019.05.004","DOI":"10.1016\/j.therap.2019.05.004"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/6505\/18481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/6505\/18481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:10:21Z","timestamp":1686820221000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/6505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":61,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.6505","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}